Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

Open access

Abstract

The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model. However, acquired resistance to PARPi and cytotoxicity-mediated adverse effects limit their clinical applicability. Here, we detailed the role of PARP-1 as a therapeutic target in CRC and studied the efficacy of novel PARPi compounds in wildtype (WT) and DNA repair-deficient CRC cell lines together with the chemotherapeutics irinotecan (IT), 5-fluorouracil (5-FU), and oxaliplatin (OXA). Based on the ComPlat molecule archive, we identified novel PARPi candidates by molecular docking experiments in silico, which were then confirmed by in vitro PARP activity measurements. Two promising candidates (X17613 and X17618) also showed potent PARP-1 inhibition in a CRC cell-based assay. In contrast to olaparib, the PARPi candidates caused no PARP-1 trapping and, consistently, were not or only weakly cytotoxic in WT CRC cells and their BRCA2- or ATR-deficient counterparts. Importantly, both PARPi candidates did not affect the viability of nonmalignant human colonic epithelial cells. While both olaparib and veliparib increased the sensitivity of WT CRC cells towards IT, no synergism was observed for X17613 and X17618. Finally, we provided evidence that all PARPi (olaparib > veliparib > X17613 > X17618) synergize with chemotherapeutic drugs (IT > OXA) in a BRCA2-dependent manner in CRC cells, whereas ATR deficiency had only a minor impact. Collectively, our study identified novel lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity due to the lack of PARP-1 trapping, which synergized with IT in homologous recombination deficiency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16203441

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure A1 (A) Binding modes of selected compounds from virtual screening ((1–4), PDB: 4PJT) to PARP-1. The binding to either G863 or S904 was used as a constraint in docking. All active compounds are able to form this bond and adopt a similar binding mode (compare Figure 1A). The three compounds X17611, X17610, and X17608 (1–3) serve as a verification of the binding mode since the constraints can only be fulfilled with significant losses in the binding free energy due to unfavorable inter- and intramolecular interactions. X17616 (4) is similar to X17618 (Figure 1A), but cannot form a potential hydrogen bond due to the lack of the amide function. (B) Chemical structure of the compounds X17611, X17610, X17608 and X17616.
Figure A1 (A) Binding modes of selected compounds from virtual screening ((1–4), PDB: 4PJT) to PARP-1. The binding to either G863 or S904 was used as a constraint in docking. All active compounds are able to form this bond and adopt a similar binding mode (compare Figure 1A). The three compounds X17611, X17610, and X17608 (1–3) serve as a verification of the binding mode since the constraints can only be fulfilled with significant losses in the binding free energy due to unfavorable inter- and intramolecular interactions. X17616 (4) is similar to X17618 (Figure 1A), but cannot form a potential hydrogen bond due to the lack of the amide function. (B) Chemical structure of the compounds X17611, X17610, X17608 and X17616.CC BY · PubMed Central
Figure A2 (A,B) Concentration response curve of established PARP inhibitors veliparib and olaparib (A) and eight potential PARP inhibitors (B) with low or no activity in the PARP-1 screening assay kit. All concentrations were tested in duplicates. IC50 values were derived using a nonlinear regression model in GraphPad Prism 9 (n = 2).
Figure A2 (A,B) Concentration response curve of established PARP inhibitors veliparib and olaparib (A) and eight potential PARP inhibitors (B) with low or no activity in the PARP-1 screening assay kit. All concentrations were tested in duplicates. IC50 values were derived using a nonlinear regression model in GraphPad Prism 9 (n = 2).CC BY · PubMed Central
Figure A3 (A) Concentration-response curves of 4 potential PARP-1 inhibitors (X17613, X17618, X17620 and X17621) assessed in HCT116 cells as described in Figure 2B (n = 3). IC50 values were derived using a nonlinear regression model in GraphPad Prism 9. (B) Representative confocal microscopy images at 100× magnification after PAR staining in HCT116 cells treated with the indicated concentrations of X17618 for 2 h with or without subsequent PARP induction by H2O2 treatment for 5 min. Scale bar: 100 µm. (C) Confocal microscopy images at 630× magnification after pan-PAR staining in HCT116 treated as described in B. Scale bar: 20 µm.
Figure A3 (A) Concentration-response curves of 4 potential PARP-1 inhibitors (X17613, X17618, X17620 and X17621) assessed in HCT116 cells as described in Figure 2B (n = 3). IC50 values were derived using a nonlinear regression model in GraphPad Prism 9. (B) Representative confocal microscopy images at 100× magnification after PAR staining in HCT116 cells treated with the indicated concentrations of X17618 for 2 h with or without subsequent PARP induction by H2O2 treatment for 5 min. Scale bar: 100 µm. (C) Confocal microscopy images at 630× magnification after pan-PAR staining in HCT116 treated as described in B. Scale bar: 20 µm.CC BY · PubMed Central
Figure A4 (A) Western Blot analysis of PARP-1, BRCA2 and ATR expression in HCT116 WT, HCT116 BRCA2−/−, HCT116 PARP-1+/+, HCT116 PARP-1−/−, DLD-1 WT and DLD-1 ATR−/− cells. HSP90 served as loading control. (B) Toxicity of PARPi in human colonic epithelial cells (HCEC). Cells were incubated with PARPi for 72 h and viability was assessed using the RRA. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3).
Figure A4 (A) Western Blot analysis of PARP-1, BRCA2 and ATR expression in HCT116 WT, HCT116 BRCA2−/−, HCT116 PARP-1+/+, HCT116 PARP-1−/−, DLD-1 WT and DLD-1 ATR−/− cells. HSP90 served as loading control. (B) Toxicity of PARPi in human colonic epithelial cells (HCEC). Cells were incubated with PARPi for 72 h and viability was assessed using the RRA. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3).CC BY · PubMed Central
Figure A5 Cell viability of (A) HCT116 WT and HCT116 BRCA2−/−, (B) HCT116 PARP-1+/+ and HCT116 PARP-1−/−, (C) DLD-1 WT and DLD-1 ATRs/s, (D) Caco-2 cells and (E) HCEC after monotreatment with cytostatic drugs IT, 5-FU and OXA for 72 h. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3).
Figure A5 Cell viability of (A) HCT116 WT and HCT116 BRCA2−/−, (B) HCT116 PARP-1+/+ and HCT116 PARP-1−/−, (C) DLD-1 WT and DLD-1 ATRs/s, (D) Caco-2 cells and (E) HCEC after monotreatment with cytostatic drugs IT, 5-FU and OXA for 72 h. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3).CC BY · PubMed Central
Figure A6 (A) Viability of HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi X17618 in combination with chemotherapeutic drugs irinotecan (IT, 0.5 µM), 5-fluorouracil (5-FU, 0.25 µM) and oxaliplatin (OXA, 0.5 µM) for 72 h (n ≥ 3) (B) Viability of HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi X17618 in combination with chemotherapeutic drugs irinotecan (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (C) γH2AX formation in HCT116 WT and BRCA2−/− cells after treatment with X17618 (50 µM), IT (0.25 µM) or a combination of both for 24 h. Representative Western blot images and densitometric evaluation are shown (n = 4). All data are presented as mean +/− SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.
Figure A6 (A) Viability of HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi X17618 in combination with chemotherapeutic drugs irinotecan (IT, 0.5 µM), 5-fluorouracil (5-FU, 0.25 µM) and oxaliplatin (OXA, 0.5 µM) for 72 h (n ≥ 3) (B) Viability of HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi X17618 in combination with chemotherapeutic drugs irinotecan (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (C) γH2AX formation in HCT116 WT and BRCA2−/− cells after treatment with X17618 (50 µM), IT (0.25 µM) or a combination of both for 24 h. Representative Western blot images and densitometric evaluation are shown (n = 4). All data are presented as mean +/− SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.CC BY · PubMed Central
Figure A7 (A) Viability of DLD-1 WT and DLD-1 ATRs/s cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs (IT, 2.5 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 5 µM) for 72 h (n ≥ 3). (B) Viability of DLD-1 WT and DLD-1 ATRs/s cells after treatment with PARPi X17613 and X17618 in combination with chemotherapeutic drugs (IT, 2.5 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 5 µM) for 72 h (n ≥ 3). Data are shown as mean +/− SEM. * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.
Figure A7 (A) Viability of DLD-1 WT and DLD-1 ATRs/s cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs (IT, 2.5 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 5 µM) for 72 h (n ≥ 3). (B) Viability of DLD-1 WT and DLD-1 ATRs/s cells after treatment with PARPi X17613 and X17618 in combination with chemotherapeutic drugs (IT, 2.5 µM), 5-fluorouracil (5-FU, 0.1 µM) and oxaliplatin (OXA, 5 µM) for 72 h (n ≥ 3). Data are shown as mean +/− SEM. * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.CC BY · PubMed Central
Figure 1 (A) Binding modes of veliparib (1), PDB: 7AAC), olaparib ((2), PDB: 7AAD), and selected compounds from virtual screening ((3–9), PDB: 4PJT) to PARP-1. The binding to either G863 or S904, as also found for veliparib, was used as a constraint in docking. All active compounds are able to form this bond and adopt a similar binding mode. Through the indole NH, there is an interaction with E988 by a bridging water molecule. No preference between the binding modes of the S- (4–6) or R-enantiomers (7–9) is observed, while the scoring values also differ only slightly. (B) Chemical structure of the most active compounds X17613, X17618, X17620, and X17621, according to in vitro screening and the two established PARPi veliparib and olaparib.
Figure 1 (A) Binding modes of veliparib (1), PDB: 7AAC), olaparib ((2), PDB: 7AAD), and selected compounds from virtual screening ((3–9), PDB: 4PJT) to PARP-1. The binding to either G863 or S904, as also found for veliparib, was used as a constraint in docking. All active compounds are able to form this bond and adopt a similar binding mode. Through the indole NH, there is an interaction with E988 by a bridging water molecule. No preference between the binding modes of the S- (4–6) or R-enantiomers (7–9) is observed, while the scoring values also differ only slightly. (B) Chemical structure of the most active compounds X17613, X17618, X17620, and X17621, according to in vitro screening and the two established PARPi veliparib and olaparib.CC BY · PubMed Central
Figure 2 (A) Concentration–response curves of four potential PARP-1 inhibitors with the highest activity in the PARP-1 screening assay kit. All concentrations were tested in duplicates. IC50 values were derived using a nonlinear regression model in GraphPad Prism 9 (n = 2). (B) Investigation of PARP inhibition by X17613, X17618, X17620, and X17621 in HCT116 cells. Cells were challenged with 1 mM H2O2 for 5 min and pretreated or not with the indicated compounds for 2 h. PAR synthesis was identified by confocal IF microscopy using the PAR 10H antibody. The signal intensity of five images per concentration was evaluated by ImageJ (n ≥ 3). (C) Representative confocal microscopy images at 100× magnification after PAR staining in HCT116 cells treated with the indicated concentrations of X17613 for 2 h with or without subsequent PARP activation by H2O2 treatment for 5 min. Scale bar: 100 µm. (D) Confocal microscopy images at 630× magnification after pan-PAR staining in HCT116 cells treated according to (C). Scale bar: 20 µm. Data are presented as mean +/− SEM. * p < 0.01, ** p < 0.01; t-test.
Figure 2 (A) Concentration–response curves of four potential PARP-1 inhibitors with the highest activity in the PARP-1 screening assay kit. All concentrations were tested in duplicates. IC50 values were derived using a nonlinear regression model in GraphPad Prism 9 (n = 2). (B) Investigation of PARP inhibition by X17613, X17618, X17620, and X17621 in HCT116 cells. Cells were challenged with 1 mM H2O2 for 5 min and pretreated or not with the indicated compounds for 2 h. PAR synthesis was identified by confocal IF microscopy using the PAR 10H antibody. The signal intensity of five images per concentration was evaluated by ImageJ (n ≥ 3). (C) Representative confocal microscopy images at 100× magnification after PAR staining in HCT116 cells treated with the indicated concentrations of X17613 for 2 h with or without subsequent PARP activation by H2O2 treatment for 5 min. Scale bar: 100 µm. (D) Confocal microscopy images at 630× magnification after pan-PAR staining in HCT116 cells treated according to (C). Scale bar: 20 µm. Data are presented as mean +/− SEM. * p < 0.01, ** p < 0.01; t-test.CC BY · PubMed Central
Figure 3 (A,B) Analysis of PARP-1 trapping in HCT116 and Caco-2 cells. Immunoblot detection of PARP-1 after pre-treatment with X17613, X17618, and olaparib followed by MMS exposure for 1 h and chromatin isolation. The cytosolic marker Hsp90 and the chromatin marker Histone H3 served as respective loading controls. Representative Western blot images and densitometric evaluation are shown (n = 3). Data are shown as mean + SEM. (C) Cell viability determined by the resazurin reduction assay (RRA) in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after PARPi treatment for 72 h. A nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). (D) Viability in Caco-2 cells after exposure to PARPi as indicated. (n = 3). All data are shown as mean +/− SEM.
Figure 3 (A,B) Analysis of PARP-1 trapping in HCT116 and Caco-2 cells. Immunoblot detection of PARP-1 after pre-treatment with X17613, X17618, and olaparib followed by MMS exposure for 1 h and chromatin isolation. The cytosolic marker Hsp90 and the chromatin marker Histone H3 served as respective loading controls. Representative Western blot images and densitometric evaluation are shown (n = 3). Data are shown as mean + SEM. (C) Cell viability determined by the resazurin reduction assay (RRA) in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after PARPi treatment for 72 h. A nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). (D) Viability in Caco-2 cells after exposure to PARPi as indicated. (n = 3). All data are shown as mean +/− SEM.CC BY · PubMed Central
Figure 4 (A) Toxicity of PARPi in HCT116 cells depending on BRCA2 status. HCT116 WT and HCT116 BRCA2−/− cells were incubated with PARPi for 72 h and viability was assessed using the resazurin reduction assay (RRA). Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). (B) Toxicity of PARPi in DLD-1 cells depending on ATR status. DLD-1 WT and DLD-1 ATRs/s cells were incubated with PARPi for 72 h and viability was assessed using the RRA. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). Data are depicted as mean +/− SEM.
Figure 4 (A) Toxicity of PARPi in HCT116 cells depending on BRCA2 status. HCT116 WT and HCT116 BRCA2−/− cells were incubated with PARPi for 72 h and viability was assessed using the resazurin reduction assay (RRA). Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). (B) Toxicity of PARPi in DLD-1 cells depending on ATR status. DLD-1 WT and DLD-1 ATRs/s cells were incubated with PARPi for 72 h and viability was assessed using the RRA. Nonlinear regression curve fit was conducted using GraphPad Prism 9 (n ≥ 3). Data are depicted as mean +/− SEM.CC BY · PubMed Central
Figure 5 (A) Viability in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs irinotecan (IT, 0.5 µM), 5-fluorouracil (5-FU, 0.25 µM), and oxaliplatin (OXA, 0.5 µM) for 72 h (n ≥ 3). (B) Viability in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi X17613 in combination with chemotherapeutic drugs for 72 h. Data (n ≥ 3) are given as mean +/− SEM. (C,D) Viability in Caco-2 cells after treatment with PARPi in combination with chemotherapeutic drugs irinotecan (IT, 10 µM), 5-fluorouracil (5-FU, 5 µM), and oxaliplatin (OXA, 1 µM). Data (n = 3) are shown as mean +/− SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.
Figure 5 (A) Viability in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs irinotecan (IT, 0.5 µM), 5-fluorouracil (5-FU, 0.25 µM), and oxaliplatin (OXA, 0.5 µM) for 72 h (n ≥ 3). (B) Viability in HCT116 PARP-1−/− and HCT116 PARP-1+/+ cells after treatment with PARPi X17613 in combination with chemotherapeutic drugs for 72 h. Data (n ≥ 3) are given as mean +/− SEM. (C,D) Viability in Caco-2 cells after treatment with PARPi in combination with chemotherapeutic drugs irinotecan (IT, 10 µM), 5-fluorouracil (5-FU, 5 µM), and oxaliplatin (OXA, 1 µM). Data (n = 3) are shown as mean +/− SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01, *** p < 0.001, **** p < 0.0001; t-test.CC BY · PubMed Central
Figure 6 (A) Viability in HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM), and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (B) Viability in HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi X17613 in combination with chemotherapeutic drugs (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM), and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (C) Representative brightfield microscopic images at 20X magnification of HCT116 WT and HCT116 BRCA2−/− cells after treatment with X17613 (50 µM), IT (0.25 µM), or a combination of both for 24 h. (D,E) γH2AX formation in HCT116 WT and BRCA2−/− cells after treatment as described in (C). Representative Western blot images and densitometric evaluation are shown (n = 4). Hsp90 served as loading control. All data are given as mean + SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01; t-test.
Figure 6 (A) Viability in HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi olaparib or veliparib in combination with chemotherapeutic drugs (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM), and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (B) Viability in HCT116 WT and HCT116 BRCA2−/− cells after treatment with PARPi X17613 in combination with chemotherapeutic drugs (IT, 0.25 µM), 5-fluorouracil (5-FU, 0.1 µM), and oxaliplatin (OXA, 0.25 µM) for 72 h (n ≥ 3). (C) Representative brightfield microscopic images at 20X magnification of HCT116 WT and HCT116 BRCA2−/− cells after treatment with X17613 (50 µM), IT (0.25 µM), or a combination of both for 24 h. (D,E) γH2AX formation in HCT116 WT and BRCA2−/− cells after treatment as described in (C). Representative Western blot images and densitometric evaluation are shown (n = 4). Hsp90 served as loading control. All data are given as mean + SEM. ns: p > 0.05, * p < 0.01, ** p < 0.01; t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 14

Metadata

Authors
Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., & Fahrer, J.
Affiliations
  • Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau (DE)
  • Universität Greifswald (DE)
  • Karlsruhe Institute of Technology (DE)
  • Christian-Albrechts-Universität zu Kiel (DE)
  • Institute of Molecular Biology (DE)
Corresponding author
Fahrer, Jörg
Venue
Cancers
Publisher
MDPI AG
Published
2024-10-10
Volume
16
Issue
20
Pages
3441
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4403298139
Cited by
14
References
75
Citations by year
2026: 7 · 2025: 7
FWCI
2.40
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository KITopen (Karlsruhe Institute of Technology) (submittedVersion, cc-by)
  • KITopen (cc-by)
Funders
  • German Research Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
  • Wilhelm Sander Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
PARP1 inhibition, PARP inhibitors, colorectal cancer, olaparib, veliparib, irinotecan, oxaliplatin, 5-fluorouracil, DNA damage response, BRCA2 deficiency, homologous recombination deficiency, drug synergy, molecular docking, cytotoxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. https://app.cochat.ai/papers/10.3390/cancers16203441
The paper
Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., & Fahrer, J. (2024). Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. Cancers. https://doi.org/10.3390/cancers16203441

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.